Navigation Links
Millennium Expands IBD Franchise with Addition of New Development Candidate
Date:3/17/2008

- Company advances oral antagonist of CCR9, a chemokine receptor believed

to play a critical role in Crohn's disease -

CAMBRIDGE, Mass., March 17 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the advancement of MLN3126, a new product candidate, from the Company's discovery engine to its development pipeline. MLN3126 is a selective antagonist of CCR9, a chemokine receptor known to be important in the migration of inflammatory cells into the gastrointestinal tract. Along with MLN0002, an antibody targeting the alpha4beta7 integrin, MLN3126 expands the Company's inflammatory bowel disease (IBD) franchise. MLN0002 already has demonstrated the ability to induce clinical remission in patients with ulcerative colitis and Crohn's disease and is expected to enter pivotal Phase III trials in late 2008 or early 2009 in both indications.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"The development of MLN3126 leverages our knowledge and experience in the area of IBD, a key focus area for Millennium," said Deborah Dunsire, M.D., Chief Executive Officer, Millennium. "Building on our scientific knowledge and broad patent estate in the area of chemokines, we have identified a product candidate that is differentiated from others in this field and potentially could benefit the millions of patients afflicted with Crohn's worldwide."

"We are delighted to move forward some very promising molecules in IBD. In addition to the positive direction of MLN3126, preliminary results from bridging studies with MLN0002 from our new commercially scalable cell line show favorable pharmaco
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Eleventh Annual Lehman Brothers Global Healthcare Conference to Webcast Millennium Presentation
2. Cowen & Company 28th Annual Healthcare Conference to Webcast Millennium Presentation
3. 2008 Susquehanna Healthcare Conference to Webcast Millennium Presentation
4. BIO CEO & Investor 2008 Conference to Webcast Millennium Presentation
5. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
6. Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology
7. Millennium Enters Into $600,000 Product Development Agreement to Fund Product Development for the $20,000,000 Purchase Agreement with Provider Services, Inc.
8. Millennium to Webcast Business Update in Advance of 26th Annual JPMorgan Healthcare Conference
9. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
10. Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event
11. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2010)... Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... ... WASHINGTON , March 18 Kids in New Jersey will take center stage in the fight against tobacco on March ...
(Date:3/18/2010)... ... , , ... ... ... New Hampshire will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide ...
(Date:3/18/2010)... President and CEO, Legacy(SM) , ... , , ... ... WASHINGTON , March ... ...
(Date:3/18/2010)... of U.S. medical students choosing internal medicine residencies ... significantly impact the shortage of primary care physicians. ... Program report, 2,722 U.S. seniors at medical schools ... 3.4 percent increase from 2,632 in 2009. The ... (2,660), 2007 (2,680), and 2006 (2,668). In comparison, ...
(Date:3/18/2010)... In its 21-year history, under the ... leaders, SRLA has trained more than 40,000 teenagers from ... area to complete the 26.2 mile Los Angeles Marathon. ... volunteer leaders will again participate in the LA Marathon. ... SRLA,s mission is to challenge at-risk secondary students to ...
Breaking Medicine News(10 mins):Health News:New Jersey Kids 'Kick Butts' on March 24 2Health News:New Jersey Kids 'Kick Butts' on March 24 3Health News:New Jersey Kids 'Kick Butts' on March 24 4Health News:New Jersey Kids 'Kick Butts' on March 24 5Health News:New Hampshire Kids 'Kick Butts' on March 24 2Health News:New Hampshire Kids 'Kick Butts' on March 24 3Health News:New Hampshire Kids 'Kick Butts' on March 24 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5Health News:Residency match results not encouraging for adults needing primary care 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 3
... findings might boost understanding of the disease generally, researchers ... adult children of people with the rarer, inherited form ... study to better understand the biology of the brain ... parent diagnosed with a known genetic mutation causing the ...
... anticipation of World AIDS Day on Monday, December 1, the Global ... the US effort against HIV/AIDS, both at home and abroad, and ... Over 100 global health advocacy organizations have signed a memo to ... take on HIV/AIDS and related issues. The memo is online: ...
... Cross and Blue,Shield in Maine announced today that its ... organizations as part of the company,s,annual Associate Giving Campaign. ... 50 percent of associate pledges, increasing the total to,more ... "Every day our associates work to make a positive ...
... new national screening strategy in Denmark has halved the ... the number of infants diagnosed before birth by 30%, ... today. , Many countries, including England, Australia and New ... Down,s syndrome, but are facing a variety of problems ...
... of biochemists has discovered how an experimental drug unleashes ... (TB). The finding could help scientists develop ways to ... drug development against other bacteria as well. , ... Barry, III, Ph.D., of the National Institute of Allergy ...
... statistics show that nearly 4,000 people in the UK die each year from ... ... -- On 24th November 1999, the Government,s ban on the use of ... people in the UK die each year from the effects of asbestos exposure ...
Other Medicine News:Health News:Study Recruiting From Alzheimer's-Prone Families 2Health News:World AIDS Day December 1st: Obama Needs to Lead 2Health News:Anthem Blue Cross and Blue Shield in Maine Associates Pledge More Than $277,500 to Community Organizations 2Health News:New screening halves the number of children born with Down syndrome 2Health News:Experimental TB drug explodes bacteria from the inside out 2Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 2Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 3
(Date:3/18/2010)... March 18 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that the U.S. Patent ... the composition of matter patent for picoplatin as RE41209, ... 2010 . The reissue was applied for May ... , the USPTO released the "Issue Notification" for the ...
(Date:3/18/2010)... , March 18 ... Chief Executive Officer, Pfizer, was elected board ... of America (PhRMA) today at the trade ... Chief Executive Officer Christopher Viehbacher ... Directors, and John C. Lechleiter , ...
(Date:3/18/2010)... results in too much ammonia in the blood. , ... , , ... ... (Logo: ... ...
Breaking Medicine Technology:U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 2U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 3U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 4U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 2FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 3FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 4FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 5Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3Exposure to lead tobacco smoke raises risk of ADHD 10856 1Exposure to lead tobacco smoke raises risk of ADHD 10856 2Measuring and modeling blood flow in malaria 61892 1Measuring and modeling blood flow in malaria 61892 2
... Sept. 26 Threshold,Pharmaceuticals, Inc. (Nasdaq: THLD ... trial of glufosfamide plus gemcitabine were presented at ... Spain. In the Phase 2 clinical trial ... of advanced pancreatic cancer, six-month and,one-year survival were ...
... and BERLIN, Sept. 26 ,Genzyme Corporation (Nasdaq: ... announced that the first patient has been treated ... examining the safety and efficacy of alemtuzumab for,the ... I trial (Comparison of Alemtuzumab and Rebif Efficacy ...
Other Medicine Technology:Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) 2Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) 3Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) 4Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 2Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 3Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 4Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 5Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 6
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... line of flowmeters, available in oxygen, ... They are all available in a ... your application. With color coded labels ... in use, the Amvex Flowmeter is ...
... a complete line of flowmeters, available ... 2 . They are all available ... best suit your application. With color ... the gas in use, the Amvex ...
... complete line of flowmeters, available in oxygen, air, heliox ... a variety of calibrations to best suit your application. ... gas in use, the Amvex Flowmeter is a user ... with I. For Power Take-Off add PT to the ...
Medicine Products: